Subarachnoid Hemorrhage Due to Systemic Lupus Erythematosus Associated with Multiple Intracranial Artery Aneurysms

0
0
0

Subarachnoid Hemorrhage Due to Systemic Lupus Erythematosus Associated with Multiple Intracranial Artery Aneurysms

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by systemic inflammation and multiorgan involvement. While cardiovascular complications such as premature atherosclerosis, vasculitis, and coagulopathy are well-documented in SLE, cerebrovascular manifestations, particularly subarachnoid hemorrhage (SAH) secondary to cerebral aneurysms, remain rare and poorly understood. This report presents a case of rapid development of multiple intracranial aneurysms in a young patient with active SLE, highlighting the challenges in pathogenesis, diagnosis, and management.

Case Presentation

A 21-year-old female with a one-year history of SLE presented with fever, headache, vertigo, tinnitus, and right-sided numbness. Her initial SLE manifestations included Raynaud’s phenomenon, peripheral arthritis, erythema, proteinuria, and fever, which had been stabilized with intravenous methylprednisolone pulse therapy (IMPT: 1000 mg/d for 3 days), followed by oral prednisone (60 mg/d tapered to 5 mg/d) and cyclophosphamide (400 mg/week for 16 weeks).

One month prior to admission, she developed persistent headaches after travel, followed by intermittent fever (37.5–38.5°C). Initial cranial magnetic resonance imaging (MRI) revealed a left pontine lesion with short T1 and long T2 signals, while magnetic resonance angiography (MRA) showed no vascular abnormalities (Figure 1). Lumbar puncture demonstrated normal intracranial pressure (ICP), elevated cerebrospinal fluid (CSF) white blood cells (94/mL), and elevated protein levels (3 g/L). Laboratory findings included mildly elevated erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and hypocomplementemia. Notably, anti-nuclear antibody (ANA) and anti-dsDNA antibody titers increased significantly (1:1000 and 36.1 U/mL, respectively), while anti-phospholipid antibodies (ACL, LA, anti-β2GP1) were negative.

Disease Progression and Management

Upon transfer to the tertiary hospital, the patient received IMPT (1000 mg/d on days 3–7 and 14–16), oral prednisone (60 mg/d), intrathecal methotrexate (10 mg) with dexamethasone (10 mg weekly for 3 weeks), and cyclophosphamide (600 mg/week). Due to suspected secondary anti-phospholipid syndrome, anticoagulation with low molecular weight heparin (10 days) followed by warfarin (target INR 2.86) was initiated. Symptoms improved gradually, but low-grade fever persisted.

On day 52 of hospitalization, the patient experienced sudden severe headache without focal neurological deficits. Neurological examination revealed mild nuchal rigidity. Non-contrast computed tomography (CT) confirmed SAH in the bilateral frontal regions (Figure 2a–2b). Computed tomography angiography (CTA) identified multiple saccular aneurysms involving bilateral middle cerebral arteries (MCA), anterior cerebral arteries (ACA), posterior cerebral arteries (PCA), and superior cerebellar arteries (SCA) (Figure 2c–2f). Warfarin was discontinued, and strict bed rest was enforced for three weeks. Prednisone (60 mg/d) was continued, leading to symptom resolution and normalization of laboratory parameters.

Pathophysiological Considerations

This case illustrates three critical aspects of cerebrovascular pathology in SLE:

  1. Aneurysm Pathogenesis: The rapid development of multiple aneurysms within two months suggests an inflammatory mechanism rather than traditional atherosclerosis. Histopathological studies in SLE-related aneurysms often demonstrate transmural vasculitis with lymphocytic infiltration, leading to medial layer destruction and vessel wall weakness. The absence of hypertension, smoking, or familial predisposition in this patient supports SLE-driven vascular pathology.

  2. Vasculitis and Hemodynamic Stress: Active SLE induces endothelial dysfunction through immune complex deposition, complement activation, and cytokine-mediated inflammation. The abrupt aneurysmal formation may reflect focal hemodynamic stress at sites of vascular inflammation, exacerbated by steroid-induced vascular fragility.

  3. Thrombotic vs. Hemorrhagic Complications: While anti-phospholipid antibodies are classically associated with thrombotic events, their absence in this case suggests alternative pathways for hemorrhagic complications, possibly related to matrix metalloproteinase-mediated arterial remodeling.

Diagnostic Challenges

Key radiological features in this case include:

  • Initial Normal MRA (Figure 1): Highlights the limitations of conventional angiography in detecting early vascular inflammation preceding structural changes.
  • CTA Evidence of Multiplicity (Figure 2c–2f): Demonstrates diffuse involvement of anterior and posterior circulations, a pattern distinct from sporadic aneurysmal SAH.

Laboratory markers of disease activity (elevated ANA, anti-dsDNA, hypocomplementemia) correlated temporally with aneurysm development, suggesting a direct relationship between SLE activity and cerebrovascular pathology.

Therapeutic Implications

Management of SLE-related SAH requires balancing immunosuppression with hemorrhage risk:

  • Steroid Efficacy: High-dose glucocorticoids (prednisone 60 mg/d) controlled systemic inflammation and prevented rebleeding, underscoring their central role in active SLE.
  • Anticoagulation Dilemma: Despite theoretical thrombotic risks, anticoagulation was halted due to SAH, emphasizing the need for individualized thromboprophylaxis in SLE patients with hemorrhagic complications.
  • Cyclophosphamide and Vascular Stability: The combination of cyclophosphamide with steroids may mitigate vascular inflammation, though its long-term impact on aneurysm regression remains unproven.

Clinical Outcomes and Prognosis

The patient achieved clinical stability with resolution of SAH symptoms and normalization of inflammatory markers. Prednisone tapering was initiated prior to discharge. This favorable outcome contrasts with historical reports of high mortality in SLE-associated SAH, particularly with multiple aneurysms. Key prognostic factors include:

  • Timely Immunosuppression: Early steroid pulse therapy likely attenuated vascular inflammation before irreversible structural damage.
  • Aneurysm Multiplicity: Diffuse involvement necessitates ongoing surveillance, as new aneurysms may develop despite clinical remission.
  • Disease Activity Monitoring: Serial assessment of ANA, anti-dsDNA, and complement levels may predict vascular complications.

Comparative Analysis with Literature

Previous studies report SAH incidence in SLE ranging from 0.1% in Western cohorts to 3.9% in Japanese populations. This geographic disparity may reflect genetic differences in vascular response to inflammation or variations in diagnostic practices. Unique characteristics of SLE-related SAH include:

  • Younger Age at Onset: Median age 32 years versus 55 years in general population.
  • Posterior Circulation Predilection: 60% of SLE-associated aneurysms involve vertebrobasilar systems, versus 10–15% in non-SLE cases.
  • Angiographic Evolution: A subset of patients develop de novo aneurysms after initial negative imaging, as seen in this case.

Mechanistic Insights from Serial Imaging

The transition from normal MRA at initial presentation to multiple aneurysms on CTA within 52 days provides critical insights into aneurysm pathogenesis:

  1. Inflammatory Phase: Pontine MRI lesions (Figure 1) may represent perivascular inflammation preceding macroscopic vascular changes.
  2. Aneurysmal Transformation: Focal endothelial injury from immune complexes and matrix degradation proteins (e.g., MMP-9) likely precipitated rapid mural weakening.
  3. Hemodynamic Trigger: Fever-induced hyperdynamic circulation may have accelerated aneurysm rupture in inflamed segments.

Conclusion

This case exemplifies the aggressive vascular phenotype of SLE, where uncontrolled systemic inflammation can precipitate rapid cerebrovascular catastrophe. Clinicians must maintain high vigilance for SAH in SLE patients with active serology and neurological symptoms, even in the absence of traditional risk factors. Multidisciplinary management integrating rheumatology, neurology, and neurosurgery expertise is essential to optimize outcomes. Future research should prioritize longitudinal imaging studies to delineate the temporal relationship between SLE flares and aneurysm formation, as well as biomarkers predictive of vascular complications.

doi.org/10.1097/CM9.0000000000000022

Was this helpful?

0 / 0